# Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

> **NCT04857983** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 62 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Memantine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04857983
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-06
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-03-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857983, "Memantine Augmentation of Targeted Cognitive Training in Schizophrenia". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04857983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*